Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02462473 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry
A Phase 2 study, sponsored by Janssen Research & Development.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT02462473: Clinical Trial Phase 2 study, sponsored by Janssen Research & Development.
NCT02462473 is a Phase 2 study that was terminated before completion, run by Janssen Research & Development. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02462473, a Phase 2 study, was terminated before completion, sponsored by Janssen Research & Development.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the number of Medication Treatment Modifications (MTMs) made by the clinician at every visit when antipsychotic medication plasma levels (AMPL) results are available compared to when AMPL results are not available.
Primary Outcome
Information on MTMs derived from data collected in the clinical assessment of the schizophrenia patient (CASP) questionnaire. The CASP captured changes in medications, changes in psychosocial treatments, visit frequency, and the need for any acute interventions. The CASP comprised of 3 sections covering several parameters. The CASP captured changes in treatment options which was used to compute MTM, as well as factors in clinical decision making and the influence of antipsychotic medication plas
Interventions
- DRUG Risperidone
- DRUG Olanzapine
- DRUG Quetiapine
- DRUG Aripiprazole
- DRUG Paliperidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2015-05 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
Why NCT02462473 stopped before completion
NCT02462473 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 5 interventions - of which Risperidone is the first listed.
NCT02462473 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02462473 about?
NCT02462473 is a clinical study titled "A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry". The purpose of this study is to determine the number of Medication Treatment Modifications (MTMs) made by the clinician at every visit when antipsychotic medication plasma levels (AMPL) results are available compared to when AMPL results are not available.
What is the current status of trial NCT02462473?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2015-05. Estimated completion is 2016-01.
What interventions are being tested in trial NCT02462473?
The interventions under investigation include: Risperidone (DRUG), Olanzapine (DRUG), Quetiapine (DRUG), Aripiprazole (DRUG), Paliperidone (DRUG).
Who is sponsoring clinical trial NCT02462473?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02462473's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia